Regarding age, no statistical difference was found even though people over 41?years old showed higher levels of NAbs in the first sampling.. interval region, considering both variants (i.e., parameters and ((respectively) (Table ?(Table1).1). The median of first and second sampling were carried out, respectively, at 72 (66C75) and 138 (132C150) days post-infection for the asymptomatic group; 63 (51C84) and 141 (132C162) days for the mild group; 78 (66C90) and 153 (141165) days for the moderate group and 72 (45C90) and 135 (126C156) days for the severe group. Table 1 General and clinical characteristics of the Dihydroeponemycin study population (%). Chi-square test was performed bThe data are not normally distributed, they are represented as median (quartile 3quartile 1), the Kruskall-Wallis test was applied Statistically significant results are in bold Detection of S1 IgG antibodies against SARS-CoV-2 S1 IgG antibodies against SARS-CoV-2 were determined in the two samples from each participant by ELISA. 4.54% were seronegative in the first sample and 3.78% in the second, because an asymptomatic case seroconverted in the second sample. A third sample was taken from three participants, all of them had detectable antibodies. All seronegative participants were SARS-CoV-2 positive by RT-qPCR. It was found that the S1 IgG indices increase with severity in both samplings, with higher values in the moderate and severe group (respectively). There were no significant differences in the decline of the indices by sex or age (Table ?(Table33). Table 3 Decay of S1 IgG antibodies?and NAbs against SARS-CoV-2 respectively). Regarding age, no statistical difference was found even though people over 41?years old showed higher levels of NAbs in the first sampling.. The decline by sex or age was not significant (Table ?(Table33). Estimation of the duration of S1 IgG antibodies and NAbs using LMM To estimate the duration of S1 IgG antibodies, an exponential decay model was proposed. The parameters were obtained using a LMM that includes all participants. Based on the indices and exponential decay of the antibodies from the first and second sampling, two variants of the interval region were obtained: one Dihydroeponemycin with changes only at the origin of the curve and the second one, at the origin and the slope. The variants suggest a mean duration of A) 744?days (668C781) and B) 744?days (453C1231) (Fig.?3A). Open in a separate window Fig. 3 Estimation of the duration of S1 IgG antibodies?and NAbs against SARS-CoV-2. A S1 IgG antibodies?duration model. B NAbs duration model. The solid line indicates the median and the dashed lines represent the first and third quartiles for both variations of the pattern for corresponding types of antibodies The S1 IgG antibodies results corresponding to the third sample of the 3 participants with the longest time post-infection by SARS-CoV-2 were used to verify the models. The results show a detection of S1 IgG antibodies in a severe case up to 314?days. The S1 IgG antibodies?results of the three participants fall within the interval defined by the quartiles, of model B. Similarly to the S1 IgG Dihydroeponemycin antibodies, the duration of NAbs was modeled as a negative sigmoid COL24A1 curve, model derived from the behavior of the data. On this case, as it has been explained previously, an adaptive LMM was used. The models show that the NAbs have a duration of 267?days (215C347). In the third sampling, no neutralizing activity was detected, which is consistent with the proposed model. Discussion Antibody mediated immunity represents one of the most important mechanism in protection against viral infections [17], in the case of SARS-CoV-2 is not yet fully known. This subject of study has been of great interest without excluding mobile immunity, whose role within the protection of reinfection continues to be highlighted [18] lately. Among the seeks of the ongoing function was to handle the creation of IgG antibodies contrary to the S1 subunit, which generate the best quantity of NAbs as the RBD is contained because of it region. We discovered that 4.54% from the individuals didn’t seroconvert to S1 IgG antibodies against SARS-CoV-2. This may be because of the known truth a short-term antibody response was induced or they were not really created, mainly because was already reported for an mild or asymptomatic attacks by SARS-CoV-2 [19C21]. Monitoring.